Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Mesa, Arizona 85213


Purpose:

Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Studies 1 and 2 of 2)


Study summary:

This study is a multicenter, randomized, double-blind, double-dummy, placebo-controlled, crossover, three-attack, outpatient study in which TREXIMET® will be compared to a butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg [Fioricet]) for the acute treatment of migraine headaches. Subjects will be randomized to one of 6 possible treatment sequences (TPB, TBP, BTP, BPT, PTB, PBT where T = TREXIMET®; P = Placebo; B = Butalbital-containing Combination Medication) . Subjects will treat each of the 3 migraine attacks when pain is moderate to severe. The study will include 4 visits: (1) a Screening visit at study entry, (2) a Drug Screen visit, (3) a Randomization visit, and (4) a Final visit. The Final visit occurs either (A) upon withdrawal or (B) after treatment of 3 migraine attacks. The primary objective is to evaluate the efficacy of TREXIMET® versus BCM for the acute treatment of moderate/severe migraine. These two replicate studies were amended while ongoing to allow for the reporting of pooled data only.


Criteria:

Inclusion Criteria: - Males and females aged 18 to 65 years. Female subjects are eligible for participation if they are either of non-childbearing potential (not capable of becoming pregnant) OR of childbearing potential having a negative urine pregnancy test at screening, and using contraception if sexually active. If using oral contraceptives, the subjects should be on a stable regimen of oral contraceptives (>/= 2 months). Eligible subjects must: - have migraine with or without aura (2004 ICHD-II criteria) and must have had at least 2 attacks per month meeting these criteria in the three months prior to screening. - have documented use of Butalbital-containing Combination Medication (MCM) to have treated at least one migraine. - be able to understand how to complete the cognitive assessments and all other questionnaires programmed in an electronic diary. - be willing and able to provide written informed consent. Exclusion Criteria: A subject is not eligible if they have: - >8 migraines or >/= 15 headache days per month in total, or has retinal, basilar, or hemiplegic migraine, or secondary headaches. - taken >350mg/day of butalbital and/or other barbiturates on an equivalent dose basis, on average, over the 30 days prior to screening. - is likely to have unrecognized cardiovascular or cerebrovascular disease (based on history or risk factors). - blood pressure >/= 140/90mmHg in 2 out of 3 BP measurements or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker. - history of congenital heart disease, cardiac arrhythmias requiring medication, or a clinical significant electrocardiogram abnormality. - evidence or history of any ischemic vascular disease including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome, or signs/symptoms consistent with these. - evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold; or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening. - a history of impaired hepatic or renal function that contraindicates participation in the study. - hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID, aspirin, barbiturates, or acetaminophen (including all sumatriptan and naproxen preparations), has porphyria or has nasal polyps and asthma. - is currently taking, or has taken in the previous three months, an ergot preparation for migraine prophylaxis; or is taking a migraine or prophylactic medication that is not stabilized (i.e. a change of dose within the last 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized. - a recent history of regular use of opioids (including opioids in combination with butalbital, e.g. Fioricet with codeine) or barbiturates other than butalbital. Regular use is defined as an average of 4 days per month over the last 6 months. - taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the 2 weeks prior to screening through 2 weeks post final study treatment. - history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent (except low-dose aspirin </= 325mg/day for cardioprotective reasons). - evidence or history of any gastrointestinal surgery or GI ulceration or perforation in the past six months, gastrointestinal bleeding in the past year; or evidence or history of inflammatory bowel disease. - is pregnant, actively trying to become pregnant, breast feeding, or not willing to have pregnancy test performed. - evidence of alcohol or substance abuse within the last year or any concurrent medical or psychiatric condition which, in the investigator's judgement, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical study. - participated in an investigational drug trial within the previous four weeks or plans to participate in another study at any time during this study.


Study is Available At:


Original ID:

TRX109011/TRX109013


NCT ID:

NCT00573170


Secondary ID:


Study Acronym:


Brief Title:

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults


Official Title:

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine When Administered Dur


Overall Status:

Completed


Study Phase:

Phase 3


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

65 Years


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

GlaxoSmithKline


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Randomized, Endpoint Classification:


Number of Arms:

6


Number of Groups:

0


Total Enrollment:

375


Enrollment Type:

Actual


Overall Contact Information

Official Name:GSK Clinical Trials
Study Director
GlaxoSmithKline

Study Dates

Start Date:February 2008
Completion Date:August 2009
Completion Type:Actual
Primary Completion Date:August 2009
Primary Completion Type:Actual
Verification Date:November 2010
Last Changed Date:November 30, 2010
First Received Date:December 12, 2007
First Results Date:August 16, 2010

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Numbers of Participants Able to "Engage in Normal Activities Not Impaired" at Time of Dosing and 2, 4, 6, and 8 Hours After Dosing as Assessed by the CDQ (Clinical Disability Questionnaire)
Time Frame:At dosing and at 2, 4, 6 and 8 hours after dosing of each attack treated with study medication. All
Safety Issues:False
Description:Clinical disability for each participant was assessed using the CDQ. This scale uses one question to assess ability to perform normal or usual activities. Responses are recorded on a 5-point scale, where 1 is "normal/not impaired", 2 is "mildly impaired
Outcome Type:Secondary Outcome
Measure:Total PPMQ-R Score as Measured With the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication
Time Frame:At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were
Safety Issues:False
Description:The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total sc
Outcome Type:Secondary Outcome
Measure:Bothersomeness-of-side Effect Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication
Time Frame:At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were
Safety Issues:False
Description:The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total sc
Outcome Type:Secondary Outcome
Measure:Ease-of-Use Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication
Time Frame:At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were
Safety Issues:False
Description:The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total sc
Outcome Type:Secondary Outcome
Measure:Functionality Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication
Time Frame:At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were
Safety Issues:False
Description:The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total sc
Outcome Type:Secondary Outcome
Measure:Efficacy Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Treating a Migraine
Time Frame:At 24 hours after dosing for each attack treated with study medication. All 3 migraine attacks were
Safety Issues:False
Description:The PPMQ-R questionnaire was used to assess participant satisfaction with migraine medication; the answers are used to generate a total score and 4 subscales scores for efficacy, functionality, ease-of-use and bothersomeness-of-side effects. The total sc
Outcome Type:Secondary Outcome
Measure:Mean Stanford Sleepiness (SS) Scale Scores at Time of Dosing and at 2, 4, 6, 8, 24 and 48 Hours After Dosing
Time Frame:Dose time, 2, 4, 6, 8, 24 and 48 hours post-dose. All 3 migraine attacks were to have been treated
Safety Issues:False
Description:Participant alertness was evaluated with the 7-point modified SS scale, where 1 is "feeling active, vital, alert, wide awake", 2 is "still functioning at high levels, but not peak; able to concentrate", 3 is "awake, but relaxed; responsive but not fully a
Outcome Type:Secondary Outcome
Measure:Mean Performance Index (PI) Scores at Time of Dosing and at 2, 4, 6, 8, 24 and 48 Hours After Dosing
Time Frame:At time of dosing, and at 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study
Safety Issues:False
Description:Overall cognition was assessed with a composite score (range 0-9) called the Performance Index, as derived from the number of correct responses per minute on subtests of the Mental Efficiency Workload Test (MEWT) cognitive battery. For a particular parti
Outcome Type:Secondary Outcome
Measure:Number of Participants Who Reported a Complete Symptom-Free Response at 2, 4, 6, 8, 24 and 48 Hours After Dosing
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migr
Safety Issues:False
Description:Complete symptom-free is defined as migraine-free, neck pain-free, and sinus pain-free without the use of any rescue medication prior to the defined time point.
Outcome Type:Secondary Outcome
Measure:Number of Participants With Pain Relief at 2, 4, 6, 8, 24 and 48 Hours After Dosing Moderate or Severe Baseline Pain
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migr
Safety Issues:False
Description:Pain relief is defined as having no or mild pain and no use of rescue medication after dosing in those participants who had moderate or severe pain at dosing.
Outcome Type:Secondary Outcome
Measure:Number of Participants With Relief From Neck Pain at 2, 4, 6, 8, 24 and 48 Hours After Dosing Who Also Had the Symptom at Baseline
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migr
Safety Issues:False
Description:The number of participants with no pain and relief of neck pain in those participants for whom neck pain was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessme
Outcome Type:Secondary Outcome
Measure:Number of Participants With Relief From Sinus/Facial Pain at 2, 4, 6, 8, 24 and 48 Hours After Dosing in Those Who Also Had the Symptom at Dosing
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migr
Safety Issues:False
Description:The number of participants with no pain and relief of sinus/facial pain in those participants for whom sinus/facial pain was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequen
Outcome Type:Secondary Outcome
Measure:Number of Participants With Pain-freedom and Relief of Vomiting at 2, 4, 6, 8, 24 and 48 Hours Post-dose
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migra
Safety Issues:False
Description:The number of participants with no pain and relief of vomiting in those participants for whom vomiting was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessment
Outcome Type:Secondary Outcome
Measure:Number of Participants With Pain-freedom and Relief of Phonophobia at 2, 4, 6, 8, 24 and 48 Post-dose Time Points
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migra
Safety Issues:False
Description:The number of participants with no pain and relief of phonophobia in those participants for whom phonophobia was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed asse
Outcome Type:Secondary Outcome
Measure:Number of Participants With Pain-freedom and Relief of Photophobia at 2, 4, 6, 8, 24 and 48 Post-dose Time Points
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migra
Safety Issues:False
Description:The number of participants with no pain and relief of photophobia in those participants for whom photophobia was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed asse
Outcome Type:Secondary Outcome
Measure:Number of Participants With Pain-freedom and Relief of Nausea at 2, 4, 6, 8, 24 and 48 Post-dose Time Points
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migra
Safety Issues:False
Description:The number of participants with no pain and relief of nausea in those participants for whom nausea was present at dose time. Participants using rescue medication were removed from the participants with relief group for all subsequent timed assessments, r
Outcome Type:Secondary Outcome
Measure:Number of Participants With a Migraine-free Response 2-48 Hours After Dosing
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migr
Safety Issues:False
Description:Migraine-free is defined as pain-free with no migraine-associated symptoms (nausea, vomiting, photophobia [sensitivity to light], and phonophobia [sensitivity to sound]) with use of any rescue medication before the defined time point.
Outcome Type:Secondary Outcome
Measure:Mean Time to First Use of Rescue Medication for the Third Attack Treated With Study Medication (Attack 3)
Time Frame:From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migr
Safety Issues:False
Description:Average time until participants took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for their third migraine a
Outcome Type:Secondary Outcome
Measure:Mean Time to First Use of Rescue Medication for the Second Attack Treated With Study Medication (Attack 2)
Time Frame:From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migr
Safety Issues:False
Description:Average time until participants took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for their second migraine
Outcome Type:Secondary Outcome
Measure:Mean Time to First Use of Rescue Medication for the First Attack Treated With Study Medication (Attack 1)
Time Frame:From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migra
Safety Issues:False
Description:Average time until participants took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for the first migraine att
Outcome Type:Secondary Outcome
Measure:Number of Participants Using Rescue Medication Within 48 Hours Post Dose
Time Frame:From dose time through 48 hours post-dose for each attack treated with study medication. All 3 migra
Safety Issues:False
Description:Number of participants who took any medication to treat their migraine pain or symptoms within 48 hours after they took the first dose of study medication (placebo, Treximet, or butalbital-containing combination medication) for that attack. Participants w
Outcome Type:Secondary Outcome
Measure:Number of Participants With a Pain-free Response From 2 to 48 Hours Post-dose
Time Frame:At 2, 4, 6, 8, 24, and 48 hours post-dose for each attack treated with study medication. All 3 migra
Safety Issues:False
Description:Pain-Free is defined as having no pain and without the use of any rescue medication from the time of the initial dose of study medication for a particular migraine attack until the defined time point at 2, 4, 6, 8, 24 or 48 hours post-dose.
Outcome Type:Primary Outcome
Measure:Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose
Time Frame:From 2 to 24 hours post-dose. All 3 migraine attacks were to have been treated within 19 weeks of r
Safety Issues:False
Description:SPF 2-24 hours is defined for all participants as having no pain at 2 hours post-dose and without the return of any pain or the use of any rescue medication (any medication taken after the first dose of study medication for any migraine pain or symptoms)

Study Interventions

Intervention Type:Drug
Name:TREXIMET®
Description:Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)
Arm Name:PBT
Intervention Type:Drug
Name:Butalbital-containing Combination Medications (BCM
Description:butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]
Arm Name:PBT
Intervention Type:Drug
Name:placebo
Description:placebo
Arm Name:PBT

Study Arms

Study Arm Type:Other
Arm Name:TPB
Description:TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
Study Arm Type:Other
Arm Name:TBP
Description:TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
Study Arm Type:Other
Arm Name:BTP
Description:BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
Study Arm Type:Other
Arm Name:BPT
Description:BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
Study Arm Type:Other
Arm Name:PTB
Description:placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
Study Arm Type:Other
Arm Name:PBT
Description:placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:GlaxoSmithKline

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Reference
Citation:Wenzel RG, Sarvis CA. Do butalbital-containing products have a role in the management of migraine? Pharmacotherapy. 2002 Aug;22(8):1029-35. Review.
PMID:12173787
Reference Type:Reference
Citation:Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia. 2004 Jun;24(6):483-90.
PMID:15154858
Reference Type:Reference
Citation:Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache. 2001 Nov-Dec;41(10):953-67. Review.
PMID:11903523

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.